In this section, we'll explore how MRD testing is changing clinical trials and what exciting developments are on the horizon for patients.

One of the biggest areas of interest is whether the U.S. Food and Drug Administration (FDA) will approve minimal residual disease as a valid primary endpoint in multiple myeloma clinical trials. That would speed up the clinical development process, and effective therapies could be used widely sooner. 

As of March 2025, the FDA has not officially approved Minimal Residual Disease (MRD) as a primary endpoint in clinical trials for multiple myeloma. 

Read on to learn about the current role of MRD in clinical trials and how emerging research could lead to potential changes. You can find additional resources to deepen your understanding of this subject in the “Continue Your Learning” subsection later on.